(A) Leukemia-free survival after haploHSCT in children with ALL according to number of alloHSCTs performed in participating transplant centers. (B) Cumulative incidence of relapse after haploHSCT in children with ALL according to number of alloHSCTs performed in participating transplant centers. (C) Cumulative incidence of nonrelapse mortality in patients with ALL in remission only, according to number of haploHSCTs.